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Abstract Ovariancancercanbecuredinupto90%ofcasesif
diagnosed early. CA125, the most studied ovarian cancer
biomarker, exhibits poor sensitivity for detecting early disease
stages and low specificity to malignancy. RECAF, the alpha-
fetoprotein receptor, is a wide-spectrum oncofetal antigen with
clinical potential for cancer diagnosis, screening, and monitor-
ing. This study evaluated the performance of RECAF as a
diagnostic tool and the sensitivity of a combination of RECAF
and CA125 to detect early stages of ovarian cancer at a cutoff
resulting in 100% specificity among healthy women. This
retrospective case–control study was designed to measure the
serum levels ofRECAF andCA125 innormalindividuals (n=
106) and cancer patients stages I/II (RECAF, n=32; CA125,
n=35) and III/IV (RECAF, n=49; CA125, n=51). A
competitive chemiluminescence assay was developed to
measure the circulating RECAF. To eliminate any false
positives, we classified as positive any patient with a RECAF
or a CA125 value higher than their respective 100%
specificity cutoff. We have shown that RECAF discriminated
cancer and healthy donors better than CA125, particularly in
the early stages (AUCRECAF=0.96 and AUCCA125=0.805).
CA125 sensitivity was lower in the early stages than in the
advance stages; RECAF sensitivity was high at all stages. A
combination of CA125 and RECAF detected three out of four
early-stage patients, with no false positives. In conclusion, the
combination of RECAF and CA125 serum values provides
the specificity and the sensitivity necessary to screen for
ovarian cancer and in particular, to detect early stages of the
disease.
Keywords RECAF.CA125.Cancer markers.Ovarian
cancer.Biomarkers.Alpha-fetoprotein.AFP.Receptor.
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Introduction
Early detection of cancer greatly increases the chances for a
successful treatment. Among the tools developed during the
past few decades, circulating biomarkers represent a simple
non-invasive promising approach for improving detection,
diagnostic, and management of some type of cancer [1, 2].
We have previously shown that RECAF, the receptor for
the circulating fetal protein alpha-fetoprotein (AFP), is a
wide-spectrum oncofetal antigen with a clinical potential
for diagnosis, screening, and follow-up of treated patients
[3]. RECAF plays a role in the internalization of circulating
AFP by immature cells from most fetal tissues, and it has
been suggested that the purpose of this internalization is to
transport and to deliver polyunsaturated fatty acids into
fetal cells [4–7]. RECAF is downregulated when embryonic
cells and tissue structures approach a high degree of
differentiation, thus preventing the uptake of AFP, even if
the AFP blood concentration is still high and/or increasing
[5]. We and others have shown that malignant cells regain
the ability to take up AFP and demonstrated the expression
of RECAF in a variety of cancer cells, but not in their
mature counterparts [3, 8–11].
RECAFisnotasinglemolecule;thereareatleasttwomain
membrane fractions and two main soluble cytoplasmic
J. Tcherkassova:C. Abramovich: R. Moro: C. Chen:
R. Schmit:A. Gerber
Pacific Biosciences Research Centre,
Richmond, BC, Canada
R. Moro (*)
BioCurex,
215-7080 River Road,
Richmond, BC, Canada V6X 1X5
e-mail: rmoro@biocurex.com
Tumor Biol. (2011) 32:831–838
DOI 10.1007/s13277-011-0186-1components that can be released from cancer cells either
activelyorafterthecellsdie[11–14]. Using a polyclonal anti-
RECAF antibody, we have previously developed a serum
RECAF radioimmunoassay that demonstrated a higher
concentration of serum RECAF in all types of cancer studied
(breast, prostate, lung, stomach, and ovary) [3]. Importantly,
the majority of benign tumors studied was RECAF negative,
which indicates a potential use for RECAF in combination
with tissue-specific markers for diagnosis of disease in which
the prevalent tumor biomarker could be elevated in benign
lesions. One such example is benign prostate hyperplasia, in
which PSA is often elevated above the cutoff level for
normal individuals [15].
Ovarian cancer can be cured in up to 90% of cases if
diagnosed while still limited to the ovaries (stage I/II) [16].
However, early stages are asymptomatic, and the majority
of patients is diagnosed with advanced disease (stage
III/IV), in which only 20% or less can be cured [17]. Thus,
despite being one tenth as common as breast cancer,
ovarian cancer is three times more lethal [18]. According
to the National Cancer Institute, it is estimated that in the
USA alone, 21,880 women will be diagnosed with ovarian
cancer and 13,850 women will die of it in 2010 (http://seer.
cancer.gov/statfacts/html/ovary.html), placing ovarian can-
cer as the fourth leading cause of cancer death in women
[18–21].
The development of earlier detection tests for ovarian
cancer is challenging because of the low prevalence of the
disease [18]. Current approaches to screening include
transvaginal sonography (TVS), serum markers, and two-
stage strategies that use alterations in serum markers to
prompt sonographic examination [22]. Among the serum
markers, CA125, a mucin produced by ovarian cancer cells,
has been studied most extensively [23–25]. However,
CA125 exhibits poor sensitivity for detecting early-stage
disease and has low specificity to malignancy [25].
To facilitate the discovery of novel biomarkers for early
ovarian cancer detection, the USA Congress introduced the
Ovarian Cancer Biomarker Act (legislation S. 2569), which
mandate is to amend the Public Health Service Act to
authorize the Director of the National Cancer Institute to
make grants for the discovery and the validation of
biomarkers for use in risk stratification for, and the early
detection and screening of, ovarian cancer, as explained in
the Office of Legislative Policy and Analysis website
(http://olpa.od.nih.gov/legislation/110/pendinglegislation/
Ovarian_Cancer_Biomarker.asp. ) .H o w e v e r ,i ti sw o r t h
noting that the likelihood that a single marker will fulfill
the diagnostic efficiency required for its implementation as
a population-based screening is hampered by the heteroge-
neity of ovarian cancer [26, 27], and therefore, a combina-
tion of biomarkers might be needed to enhance the
sensitivity of serum assays [24, 28–30].
In this paper, we present a retrospective case–control
study designed to evaluate the performance of: (1) RECAF
as a diagnostic tool and (2) the combination of RECAF and
CA125 to detect early stages (I and II) of ovarian cancer
using a cutoff high enough to eliminate false positives
among healthy women.
Materials and methods
Cell lines
All cell lines were obtained from the American Type Culture
Collection (VA, USA) and were grown in RPMI containing
10%fetalcalfserum(FCS,Invitrogen,Carlsbad,CA).MCF-7
is a human ductal breast carcinoma, HEP-G2 is a human
hepatocellular carcinoma, and NS1 is a mouse myeloma cell
line used as a partner for generating hybridomas.
Monoclonal antibody preparation
RECAFwas purifiedfromMCF-7cellextractsusinganAFP-
Sepharose column. In short, cells were incubated for 1 h at
37°C in serum-free RPMI in order to deplete them of bovine
AFP that they might have taken up from the FCS. The cells
were then trypsinized and re-suspended at a concentration of
5×10
7/ml in TBS (0.05 M Tris–HCl+0.1 M NaCl, pH 7.5).
The suspension was then sonicated for 2 min in an ice bath
using a Model 60 Sonic Dismembrator (Thermo Fisher
Scientific, Mississauga, ON) at 32 W, followed by centrifu-
gation for 10 min at 14,000 rpm in an Eppendorf Microfuge.
The total protein concentration of the supernatants was
7–12 mg/ml, as determined with the BioRad Total Protein
assay (BioRad, Hercules, CA). After adding 0.02%
thimerosal, the cell extracts were stored at −20°C until they
were used. RECAF was purified by affinity chromatography
on an AFP-Sepharose column. The AFP used in the column
was purified from the supernatant of HEP-G2 culture
medium by affinity chromatography using an in-house
produced anti-AFP monoclonal antibody and then conjugat-
ed to cyanogen bromide-activated Sepharose 4B (Sigma, St.
Louis, MO). One milliliter of MCF-7 extract was incubated
for 4 h at room temperature and under gentle agitation with
10 ml of AFP-Sepharose in 0.05 M Tris–HCl, pH 6.5. After
thorough washing, the bound RECAF was eluted using
0.8 M KCl in the same buffer. The eluate was concentrated
to 300–1,000 μg/ml using a Centricon spin 10,000 MWCO
filter (Millipore Corporation, Billerica, MA).
For the generation of monoclonal anti-RECAF anti-
bodies directed against the AFP-binding site, Balb/C mice
primed with pristane were injected IP with 100 μg of the
eluent mixed 1:1 with Freund’s complete adjuvant. Mice
were boosted twice with the purified protein in incomplete
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cell line, following a procedure described by Taggart and
Samloff [31] modified to use HAT for selection. The
screening was carried out by Western blotting and ELISA
on MCF-7 extract, as described previously [11]. Clones that
recognized the same bands as AFP on Western blots were
screened for binding to the AFP recognition site of RECAF
by cross-competition studies [11]. In short, 96-well micro-
titer plates (LockWell MaxiSorp, NUNC, Thermo Fisher
Scientific, Roskilde, Denmark) were coated with MFC-7
extract at 100 μg/ml. For antibody inhibition of AFP
binding to MCF-7 extract, twofold dilutions of antibody
starting at 100 μg/ml were mixed with a constant
concentration (0.5 μg/ml) of AFP biotinylated with NHS-
Biotin (Sigma), according to the manufacturer’s instruc-
tions. The assay was revealed with streptavidin–peroxidase
(KPL), developed with ABTS (KPL, Gaithersburg, MD),
and read at 405 nm. For AFP inhibition of antibody binding
to MCF-7 extract, twofold dilutions of AFP starting at
500 μg/ml were mixed with a constant concentration
(0.5 μg/ml) of an antibody-peroxidase conjugate produced
by the Nakane and Kawaoi method [32]. The assay was
developed with ABTS and read at 405 nm. Monoclonal
antibody typing was done using a kit from Zymed (San
Francisco, CA), according to manufacturer’s instructions.
Polyacrylamide gel electrophoresis and Western blots
Polyacrylamide gels containing 10% sodium dodecyl sulfate
(SDS) were used in a BioRad’s polyacrylamide gel electro-
phoresis (PAGE) apparatus following the standard Laemmli’s
procedure [33]. The sample buffer consisted of 4 ml of
distilled water, 1 ml of 0.5 M Tris–HCl, 0.8 ml glycerol,
1.6 ml of 10% SDS, 0.4 ml of β-mercaptoethanol, and
0.2 ml of 0.05% (w/v) bromophenol blue. Gels were run for
2 h at a constant current of 0.2 Amp (70–100 V) in a 1×
Tris–glycine running buffer in a Mini-Protein BioRad
system. Western blots were carried out according to standard
procedures, using a BioRad Mini-Transblot apparatus and
0.45 μm pore nitrocellulose membranes (BioRad). After
blocking the membranes with 1% BSA in TBS, the RECAF
bands were evidenced by incubating the membrane with a
suitable concentration of anti-RECAF antiserum or pure
AFP-biotin. Color development was obtained using diami-
nobenzidine and H2O2 after incubating the membranes with
a commercial conjugate (Sigma) of either streptavidin (for
the biotinylated-AFP) or anti-mouse immunoglobulin labeled
with horseradish peroxidase (Sigma).
RECAF labeling with acridinium
RECAF was labeled at a 40:1 molecules acridinium–
RECAF ratio as follows: 1 ml of RECAF (stock of
200 μg/ml) was mixed with 100 μlD M S Ot om a i n t a i n
acridinium (Cayman Chemical, Ann Arbor, MI) in solution.
Then, 19 μl of acridinium in DMF (stock of 4 mg/ml) was
added and mixed by inversion and incubated overnight
protected from light. The RECAF–acridinium conjugate was
dialyzed overnight at 4–6°C using Spectra/Por molecular
porous membrane tubing (12–14,000 mw cutoff, 29 mm
diameter; SpectrumLabs, Rancho Dominguez, CA) against
two changes of 5 l of PBS. Protein concentration was
determined using BioRad DC Protein Assay (DC Protein
Assay Kit II), followed by addition of ovalbumin to 0.01%
and thimerosal to 0.02%. The RECAF–acridinium solution
was stored at 4–6°C protected from light until use. Under
these conditions, the label RECAF remains functional for at
least 90 days.
CA125 immunoassay
Circulating CA125 was measured using the “Enzyme
Immunoassay Kit for Quantitative Determination of Anti-
gen CA 125” following manufacturer’s instructions
(XEMA Research & Production Co. Ltd.; Moscow, Russia,
Cat K222-2).
Chemiluminescence assay using acridinium–RECAF
The test was designed as a solid-phase competitive
immunoassay in which a constant amount of RECAF–
acridinium competed with the RECAF in the serum sample
for binding to the anti-RECAF antibody immobilized onto
the plastic plate: LockWell MaxiSorp 96-well plates were
coated overnight at 4°C with 100 μl/well containing 5 μg/ml
of anti-RECAF purified antibody in 0.1 M, pH 9.5, carbonate
buffer. After washing twice with dH2O at room temperature,
the wells were blocked for 2 h at 37°C with a proprietary
buffer. A mixture of 50 μlo fs e r u ms a m p l ea n d5 0μlo f
RECAF–acridinium at 400 ng/ml was then transferred to
the wells and incubated for 3 h at 37°C. The wells were
washed three times with dH2O at room temperature and
read on a chemiluminometer (Beckman Coulter, Brea,
CA).
Standard curve
We used several dilutions of the MCF-7 cell extract to
create a standard curve calibrated in arbitrary RECAF units,
which allowed us to normalize the RECAF measurements
from one experiment to another. The dilutions were carried
out in 3% fish gelatin–TBS, and they were processed in the
same manner as the serum samples. All sample readings
were within the range of the standards. To interpolate
values from the standard curve, we used the Logit/Log
function.
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BloodwascollectedandprocessedattheN.N.BlokhinCancer
ResearchCenterin Moscow, Russia,accordingto the standard
approved protocols. The serum samples from 80 confirmed
ovarian cancer patients (stages I/II=31 and III/IV=49), and
105 healthy women were included in the study. All cancer
serum samples were taken before administering treatment, and
the diagnoses were histologically confirmed before starting
this study. The samples were collected in sterile tubes with a
clotactivator,allowedtoclot,centrifuged,frozen,andstoredat
−20°C. Before testing, the samples were thawed, heated for
30 min at 56°C, and supplemented with 0.02% thimerosal.
Statistic analysis
For receiver operator characteristics (ROC) analysis
[34], we used Analyse-it® (Analyse-it Software, Ltd.,
Leeds, UK). To classify a case as positive or negative, we
first determined the cutoff value for each marker that
resulted in 100% specificity in our data set and then we
considered as positive any case that was above that
corresponding cutoff for either marker. The determination
coefficient (r
2) between RECAF and CA125 serum
values was determined using the Data Analysis tool in
Microsoft Excel.
Results
Characterization of the anti-RECAF monoclonal antibody
1.4G11
Among the monoclonal antibodies that we evaluated, Mab
1.4G11 was selected for further studies. The screening
criteria were similar to those previously published [11].
Briefly, a monoclonal antibody is considered to be directed
against the AFP-binding site of RECAF if the three
following conditions are met: (a) AFP and the antibody
recognize the same isolated fractions, (b) AFP in excess
inhibits the binding of the antibody to RECAF, and (c) an
excess of the antibody inhibits the binding of AFP to its
receptor. Western blot analysis of total MCF-7 extract and
purified RECAF demonstrates that Mab1.4G11 and AFP
recognize the same RECAF bands (Fig. 1). Mab1.4G11
and AFP competed with each other for binding to MCF-7
extracts, with maximal inhibition of 70% by Mab 1.4G11
against a fixed amount of AFP and of 85% by AFP against
a fixed amount of Mab 1.4G11. In combination, these
results demonstrate that Mab 1.4G11 is specific for
RECAF and that it recognizes the AFP-binding site of
the protein.
Measurement of RECAF and CA125 serum levels
in ovarian cancer patients and control
To measure serum levels of RECAF, we developed a novel
chemiluminescence assay. Forty blind samples distributed
Fig. 1 Western blot analysis with anti-RECAF antibody and AFP. Lane 1
indicates MW markers, lanes 2 and 3 indicate MCF-7 whole extract
reacted with Mab 1.4G11 and AFP, respectively, and lanes 4, 5,a n d6
indicate purified RECAF reacted with Mab 1.4G11 and AFP, respectively
Table 1 Descriptive statistics of serum RECAF and CA125 in normal and cancer patients
Samples n Median 95 Percentile Min Max Mean S.D.
RECAF (units) Healthy controls 106 2.106 5,381 0,031 7,421 2,280 1,805
Cancer all stages 81 7.664 11,305 1,917 17,216 7,805 2,582
Cancer stage I/II 32 8.112 10,043 2,142 17,216 8,082 2,715
Cancer stage III/IV 49 7.393 12,061 1,917 14,214 7,624 2,503
CA125 (units) Healthy controls 106 6.2 28.00 0.00 35.00 9.885 9.532
Cancer all stages 86 164.27 1,681.44 −0.02 1,889.53 391.91 516.81
Cancer stage I/II 35 60.20 1,308.29 −0.02 1,763.06 273.33 423.91
Cancer stage III/IV 51 251.88 1,779.82 5.41 1,889.53 473.29 561.48
834 Tumor Biol. (2011) 32:831–838within the range of measured RECAF values were
repeatedly tested to determine the intra- and inter-
variability of the assay. The intra-assay coefficient of
variation (CV) was ≤8%, and the inter-assay CV was less
than 6.5%.
Table 1 shows the descriptive statistics of RECAF and
CA125 values in the serum of healthy controls as well as
patients with various stages of ovarian cancer. Linear
regression studies demonstrated a low determination coef-
ficient between the RECAF and CA125 values in all the
samples (r
2=0.1318 [r=0.36] and in the ones containing
only cancer patients (r
2=0.0056 [r=0.07]. The low corre-
lation coefficient indicates that a combination of the two
markers would improve their individual cancer detection
performance.
ROC analysis Figure 2 shows the RECAF and CA125
ROC curves for all cancer stages (Fig. 2a), stages I and II
(Fig. 2b)a n dI I Ia n dI V( F i g .2c). The power to
discriminate between cancer and healthy donors is notice-
able higher for RECAF, particularly in early stages of
cancer, where the performance of CA125 is lower (AUC for
RECAF was 0.96 vs 0.805 for CA125). Importantly, Fig. 3a
a
b
Fig. 3 ROC analysis of cancer patients at stages I/II and III/IV. ROC
curves for a CA125 and b RECAF
a
b
c
Fig. 2 ROC analysis of RECAF and CA125. ROC curves of normal
individuals and cancer patients at a all stages (RECAF AUC=0.96,
CA125 AUC=0.889), b stages I/II (RECAF AUC=0.96, CA125 AUC=
0.805), and c stages III/IV (RECAF AUC=0.96, CA125 AUC=0.96)
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early stages as compared with advanced disease, RECAF
sensitivity is high at any stage (Fig. 3b). Together, these
results point at a potential use of RECAF serum values for
ovarian cancer diagnostic.
Combination of serum values of RECAF and CA125
Given the rarity of ovarian cancer, even with a high specific
test, very low levels of false positive classification would
result in an unacceptable number of women incorrectly
categorized as positive for the disease. Based on the lack of
correlation in the circulating levels of CA125 and RECAF,
we set up to determine whether their combination could
improve the sensitivity and the specificity of ovarian cancer
detection. For that purpose, we used a simple combination
method, which classifies as positive any patient with a
RECAF or CA125 value higher than the respective 100%
specificity cutoff. This high cutoff reduces the sensitivity of
the individual tests, but as there is no correlation between
marker values, we expected that the overall sensitivity of
the combination would reach clinically useful values.
In our group of samples, the 100% specificity cutoff
value for CA125 was 36 and 7,500 units/ml for RECAF
(Fig. 4). Table 2 shows the sensitivities of each or a
combination of the biomarkers for the different cancer
stages at 100% specificity. The addition of RECAF to
CA125 increased the sensitivity of ovarian cancer detection
from 70% to 83% for all cancer samples and from 79.6% to
88.2 for stage III/IV. For cancer stage I/II, where screening
is most useful, the marker combination detected 76% of
cancers, compared with 58.1% detected by CA125 alone.
Lowering the specificity of RECAF to 97%, while keeping
the same CA125 cutoff, increased the sensitivity for stage I/II
to 86%. Together, these results demonstrate that, by combin-
ing serum values of CA125 and RECAF, it is feasible to
obtain a screening test that will detect three out of four early-
stage ovarian cancer with no false positives among normal
women.
Discussion
In this paper, we reported the potential use of RECAF
serum values as a diagnostic tool for ovarian cancer and the
combination of RECAF and CA125 serum values as a
novel screening strategy to discriminate normal and ovarian
cancer patients with high sensitivity without compromise in
specificity. Importantly, in this retrospective case–control
study, high sensitivity values were attained with the
combination of markers at early stages, where the 5-year
survival rate is 90%, as opposed to 20% for stages III and
IV.
Ovarian cancer is known as the silent killer. Early
symptoms, if any, are vague, and the majority of patients
present with late-stage disease. The incidence of the disease
in average-risk women is 40 per 100,000 [18]. With this
relatively low frequency, any successful screening strategy
must not only have a sensitivity of greater than 75% for
early-stage disease, but also have a specificity of 99.6%
[35] to significantly decrease the probability of possible
complications associated with surgical confirmatory proce-
dures. A number of approaches have been proposed to
improve the specificity of CA125 for early detection. In an
initial screening test for ovarian cancer in experimental
multimodal multistep screening programs, women with
elevated CA125 levels generally undergo further evaluation
using TVS [36]. However, the success of this strategy is
Test Cutoff Specificity Sensitivity
All stages Stage I/II Stage III/IV
RECAF 7,500 units 100% 52.5% 54.8% 49.0%
CA125 36.00 units 100% 70.0% 58.1% 79.6%
COMBINATION 100% 83.0% 75.7% 88.2%
Table 2 Sensitivity of the tests
at 100% specificity
Fig. 4 Specificity cutoff value (100%) for CA125 and RECAF. CA125
showed a larger range of values than RECAF and required a log scale on
the x-axis
836 Tumor Biol. (2011) 32:831–838questionable. For example, in a study by Liede et al.,
women at elevated risk were screened annually with
examinations, CA125 and TVS. During the study period,
six of the eight cancers diagnosed were found to be in
advanced stages [37]. In another study of 4,526 women at
elevated risk for ovarian cancer, TVS was performed every
6 months. During the study period, there were ten ovarian,
fallopian tube, and primary peritoneal cancers, all of which
were diagnosed in advanced stages [38]. Indeed, a
drawback of this program is that its sensitivity as a whole
is limited by the sensitivity of the initial screening
biomarker used. Unfortunately, CA125 is elevated above
reference levels in only approximately 50% of patients with
clinically detectable, early-stage disease [39], which is
consistent with the 56% sensitivity found in our study for
stages I and II. Moreover, preliminary results from the
Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial shows that TVU and CA125, alone or in combination,
cannot only detect ovarian cancer, but can also produce
many false–positive test results, causing needless surgery.
Thus, a cost-effective test that does not result in a low
positive predictive value and excessive morbidity from
unnecessary surgery is highly desirable.
In the retrospective case–control study reported here,
serum RECAF was detected in elevated levels in ovarian
cancer patients when compared with normal individuals,
with levels of RECAF higher in stage III/IV than I/II. Using
ROC analysis, we showed that both RECAF and CA125
were able to discriminate between normal and cancer
patients, although RECAF performed better, especially in
early-stage disease. Moreover, the specificity of the RECAF
test did not change and was high at early and late stages;
whereas, the sensitivity of CA125 was lower in earlier
stages than in advance disease. Interestingly, similar
observations were seen with the levels of RECAF in
prostate and breast cancer (in preparation).
Combining CA125 with other markers represents a
promising approach for improving screening efficiency.
Some of the combinations examined so far show promising
results; however, their level of sensitivity/specificity is not
appropriate for use in a population-based screening [38,
40]. For example, in a recent study, the addition of serum
HE4 values to CA125 increased the sensitivity of the assay
for early detection from 73.2% to 82.9% and the specificity
from 79.2% to 87.6% [41]. The combination of CA125
with B7-H4 increased the sensitivity of early detection from
52% for CA125 alone to 65% at 97% specificity [42]. The
possibility of combining RECAF with other markers is
intriguing, in particular because of the lack of correlation
between circulating concentration and cancer stage. The
combination of RECAF and CA125 at a specificity of
100% increased the sensitivity of ovarian cancer detection
from 70% to 83% for all cancer samples and from 79.6% to
88.2% for stage III/IV. Importantly, for cancer stage I/II, the
marker combination detected 76% of cancers, compared
with 58.1% detected by CA125 alone.
Our data show that the combination of RECAF and
CA125 serum values provides the specificity and the
sensitivity necessary to screen for ovarian cancer, and in
particular, to detect early stages, where cure rates are the
highest. It should be kept in mind, however, that while
ovarian cancers can be detected with a combination of
CA125 and RECAF serum values, not all patients detected
with this method will have ovarian cancer, since RECAF is
elevated in many other cancer types [3]. Moreover, this
study did not include benign conditions. However, given
the fact that the cutoff value was set in a way that excluded
healthy individuals, any patient testing positive is likely to
have a pathology that at a minimum would require
diagnosis and in some cases, treatment. In those cases, the
result of the test should be considered as beneficial for the
patient, regardless of the specific pathology involved.
In conclusion, this study provides the framework for the
development of a strategy that could provide a cost-
effective and sensitive approach to detect early stages of
ovarian cancer and therefore, reduce disease-associated
mortality.
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